Author:
Laureline Wetterwald,Patrick Omoumi,Tu Nguyen,Stephane Cherix,Ana Dolcan,Daniela Ferraro,Chiara Saglietti,Igor Letovanec,Antonia Digklia
Abstract
AbstractBenign fibrous histiocytoma of the bone (BFHB) is a rare mesenchymal tumor, representing less than 1% of all benign bone tumors. This controversial entity is characterized by a mixture of fibroblasts arranged in a storiform pattern, varying amounts of osteoclast-type giant cells and foamy macrophages. Curettage or simple resection is usually curative. However, it was reported that up to 11% of the patients suffer from relapse. Here, we report a case of malignant transformation of BFHB after long-lasting disease stabilization under denosumab therapy.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Stout AP. Tumors of the soft tissues. Armed Forces Institute of Pathology; 1953.
2. Grohs JG, Nicolakis M, Kainberger F, Lang S, Kotz R. Benign fibrous histiocytoma of bone: a report of ten cases and review of literature. Wien Klin Wochenschr. 2002;114(1–2):56–63.
3. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70.
4. Santini-Araujo E, khalil RK, Bertoni F, Park YK, editors. Tumors and tumor-like lesions of bone. Springer Nature; 2020 May 5.
5. Bertoni F, Calderoni P, Bacchini P, Sudanese A, Baldini N, Present D, et al. Benign fibrous histiocytoma of bone. J Bone Joint Surg Am. 1986;68(8):1225–30.